EVADER™ Platform Technology
a new approach to gene therapy that builds on current technology
EVADER™ immune suppressive particles are co-administered with any AAV gene therapy to:
- Reduce antibodies and activated T cells
- Confer resistance to NAbs
- Increase AAV potency
- Enable repeat dosing
Fighting More Types of Diseases
Our EVADER platform technology can be customized for a variety of payloads, for example, gene replacement or gene editing. Repeat dosing potentially enables us to target growing organs or rapidly dividing tissues.
Our current focus is:
More Cost Effective to Develop and Deliver
The platform technology can be mobilized to target many types of genetic disorders.
Any standard capsid could potentially benefit from the addition of EVADER™ technology.
Initial nonclinical and in vivo results indicate at least a ten-fold increase in potency.
Our potent treatment can potentially be given at lower doses, which could provide lower production cost per systemic dose.
Scalable cGMP manufacturing technology is utilized.
Compelling Competitive Advantages
Sustainable Lead with Protected Intellectual Property
EVADER™ technology is based on intellectual property owned by Chameleon Biosciences and is further protected by issued IP of Chameleon co-founder Casey Maguire at Massachusetts General Hospital covering enveloped AAV.
Our work is supported by peer-reviewed research.
Scalable Purification Method for Enveloped AAV
by Dr. Casey Maguire, Chameleon Biosciences co-founder, and Collaborators:
Engineered exosomes reduce immune activation
by M Poggio et al:
Enveloped AAV with AAV6 & AAV9 for gene delivery to the brain
researched in the lab of Nathalie Cartier by Nicola Salvatore Orefice et al:
Advantages of Enveloped AAV over standard AAV
discovered by Chameleon Biosciences co-founder Dr. Casey Maguire and collaborators at Harvard University:
We are open to exploring other potential research collaborations or co-development.